The bourse asked investment bankers and lawyers to ensure drugmakers' compliance and legitimacy in sales and marketing activities, according to an internal publication the exchange sent to bankers in late July that was reviewed by Reuters.
Two banking sources familiar with the issue confirmed the information. The Shanghai exchange declined to comment.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: